News

HPV vaccination rates grow slowly


 

FROM MMWR

References

Over half, 56% of adolescents aged 13-17 years in the United States had received at least one dose of HPV vaccine, based on 2015 data from the Centers for Disease Control and Prevention’s 2015 National Immunization Survey-Teen.

From 2014 to 2015, the percentage of boys who had received at least one dose of HPV vaccine increased from 42% to 50% and the percentage in girls increased from 60% to 63%. In 2015, 35% of all adolescents (28% of boys and 42% of girls) received at least three doses of HPV vaccine.

©jarun011/Thinkstock

Despite the increases, “coverage with at least one HPV vaccine dose was lower than coverage with Tdap and MenACWY,” wrote Dr. Sarah Reagan-Steiner of the CDC and colleagues. During the time of the study, vaccination with at least one dose of the quadrivalent meningococcal conjugate vaccine (MenACWY) increased from 79% to 81% for all adolescents.

“These gaps in coverage demonstrate ongoing missed opportunities for HPV vaccination at visits when other recommended vaccines are administered,” the researchers said. “Strong clinician recommendations for HPV vaccination, and coadministration of the first HPV vaccine dose with Tdap and MenACWY vaccine at age 11-12 years during the same visit would improve HPV coverage,” they added.

Clinician resources to promote conversations with parents and adolescents about vaccination are available on the CDC website.

The findings were published Aug. 25 in the Centers for Disease Control and Prevention’s Morbidity and Mortality Weekly Report (MMWR 2016;65:850-8).

Recommended Reading

ACIP hints at move from three-dose to two-dose HPV vaccination schedule for youth
MDedge ObGyn
Zika vaccine development to get underway
MDedge ObGyn
Incidence of HPV-associated cancers on the rise
MDedge ObGyn
HPV vaccination rates not improved by increased awareness
MDedge ObGyn
Motivational interviewing for HPV vaccination well accepted by doctors
MDedge ObGyn
Zika virus RNA detected in serum beyond previously estimated time frame
MDedge ObGyn
NIH launches trial of Zika vaccine candidate
MDedge ObGyn
Two-dose HPV vaccines at younger age are noninferior to standard three-dose vaccine
MDedge ObGyn
Myth of the Month: Vaccinations in patients with Guillain-Barré syndrome
MDedge ObGyn
United States nears 1,400 cases of Zika in pregnant women
MDedge ObGyn